Furthermore, PLK1 is among Overlap66 and displays synthetic lethality with OIP5; inhibition of PLK1 using BI2356 only suppresses the growth of xenograft tumors generated by ACHN OIP5 cells but not the growth of tumor produced by ACHN EV cells, supporting a targeted and personalized therapy for pRCCs with OIP5 elevations. The gene discussed is OIP5; the disease is neoplasm.